Hematocrit Target for Phlebotomy in Polycythemia Vera
All patients with polycythemia vera should undergo phlebotomy to maintain hematocrit below 45%, regardless of sex. This universal target of <45% applies to both men and women and represents a critical threshold for preventing cardiovascular events and thrombosis 1.
Evidence Base
The recommendation stems from the landmark CYTO-PV trial, which definitively demonstrated that maintaining hematocrit <45% (versus 45-50%) reduced the composite endpoint of cardiovascular death and major thrombotic events from 9.8% to 2.7% (HR 3.91,95% CI 1.45-10.53) 1. This represents a nearly 4-fold reduction in life-threatening complications, making this the most important evidence-based target in PV management.
Key Distinction from Historical Practice
Older literature suggested sex-specific targets (≤45% for men, ≤42% for women) 2, 3, but current European LeukemiaNet guidelines from 2018 strongly recommend the universal <45% target for all patients 1. This simplified approach is based on superior outcomes data and eliminates confusion in clinical practice.
Practical Implementation
Induction Phase
- Remove 300-450 mL of blood weekly or twice weekly until hematocrit target (<45%) is achieved
- More aggressive phlebotomy schedules are appropriate for initial control
Maintenance Phase
- Continue same blood volume removal (300-450 mL per session)
- Adjust frequency based on hematocrit monitoring
- The goal is sustained control below 45%
Critical Caveat: When Hematocrit Control Alone Is Insufficient
Phlebotomy alone may be inadequate in certain situations, necessitating cytoreductive therapy:
- High-risk patients (age >60 years OR prior thrombosis history) - these patients require cytoreductive therapy in addition to phlebotomy 1
- Poor tolerance to phlebotomy frequency
- Symptomatic splenomegaly
- Severe disease-related symptoms
- Extreme thrombocytosis (>1500 × 10⁹/L)
- Marked leukocytosis (>15 × 10⁹/L)
Recent real-world data shows that 85.3% of patients have uncontrolled hematocrit ≥45% with current standard of care, and 55.4% have levels ≥50%, highlighting the challenge of achieving adequate control 4.
Adjunctive Therapy
Low-dose aspirin (81-100 mg daily) should be combined with phlebotomy in all patients unless contraindications exist (particularly acquired von Willebrand disease with extreme thrombocytosis ≥1000 × 10⁹/L) 1, 5.
Bottom Line
The minimum hematocrit indicating need for phlebotomy is 45% for both men and women - any value at or above this threshold warrants therapeutic phlebotomy. This is not a target range but rather a ceiling that should not be exceeded, as maintaining hematocrit <45% significantly reduces mortality and major thrombotic complications 1.